Lannett Company Stock Forecast for 2023 - 2025 - 2030
Updated on 04/17/2024
Lannett Company Fair Value Forecast for 2023 - 2025 - 2030
Lannett Company's Price has increased by 100.00% In the last year, going from $0.00 to $0.00. In the next year, analysts expect Fair Value to reach $0.00 – an increase of 100.00%. For the next six years, the forecast is for Fair Value to grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| TEVA Stock Forecast | Teva Pharmaceutical Industries | Outperform |
12
|
$13.18 | Buy/Sell | $11.59 | 21.40% |
| AUROPHARMA Stock Forecast | Aurobindo Pharma | Outperform |
18
|
Rp1.11k | Buy/Sell | Rp1.09k | 5.84% |
| HIK Stock Forecast | Hikma Pharmaceuticals PLC | Outperform |
18
|
£17.74 | Buy/Sell | £28.11 | 66.74% |
| RICHTER Stock Forecast | Outperform |
18
|
Ft9.06k | Buy/Sell | Ft11.02k | 29.21% | |
| APN Stock Forecast | Aspen Pharmacare Holdings | Outperform |
18
|
R224.04 | Buy/Sell | R202.49 | 2.88% |
Lannett Company Revenue Forecast for 2023 - 2025 - 2030
Lannett Company's Revenue has decreased by 37.59% In the last two years, from $545.74M to $340.58M. In the next year, analysts expect Revenue to reach $448.60M – an increase of 31.72%. For the next eight years, the forecast is for Revenue to grow by 37.38%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| KRKG Stock Forecast | Krka, d. d. | Buy |
18
|
125.00€ | Buy/Sell | 119.80€ | 14.00% |
| PRGO Stock Forecast | Perrigo Co PLC | Outperform |
16
|
$30.04 | Buy/Sell | $44.75 | 33.16% |
| GLENMARK Stock Forecast | Glenmark Pharmaceuticals | Outperform |
18
|
Rp1.06k | Buy/Sell | Rp767.80 | -14.67% |
.jpg)
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| AMPH Stock Forecast | Amphastar Pharmaceuticals | Outperform |
14
|
$40.05 | Buy/Sell | $69.00 | 54.81% |
| AMRX Stock Forecast | Amneal Pharmaceuticals | Outperform |
16
|
$5.46 | Buy/Sell | $6.13 | 37.36% |
| SUPN Stock Forecast | Supernus Pharmaceuticals | Outperform |
16
|
$29.00 | Buy/Sell | $41.00 | 37.93% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| AIP Stock Forecast | Adcock Ingram Holdings | Hold |
16
|
R54.27 | Buy/Sell | R55.97 | 3.19% |
| CHRS Stock Forecast | Coherus BioSciences | Outperform |
6
|
$2.15 | Buy/Sell | $10.86 | 272.09% |
| ASRT Stock Forecast | Assertio Holdings | Buy |
8
|
$0.78 | Buy/Sell | $3.50 | 284.62% |
Lannett Company EBITDA Forecast for 2023 - 2025 - 2030
In the last two years, Lannett Company's EBITDA has decreased by 132.08%, from $112.08M to $-35.95M. Next year, analysts are expecting EBITDA to reach $-111.80M – an increase of 210.99%. Over the next eight years, the forecast is for EBITDA to grow by 509.76%.
Lannett Company EBIT Forecast for 2023 - 2025 - 2030
In the last two years, Lannett Company's EBIT has fallen from $55.78M to $-70.22M – a 225.89% decrease. For next year, analysts predict EBIT of $-136.29M, which would mean an increase of 94.09%. Over the next eight years, experts predict that Lannett Company's EBIT will grow at a rate of 137.29%.
Lannett Company EPS Price Prediction Forecast for 2023 - 2025 - 2030
Lannett Company's EPS has increased by 100.00% In the last year, going from $0.00 to $0.00. In the next year, analysts expect EPS to reach $0.00 – an increase of 100.00%. For the next six years, the forecast is for EPS to grow by 100.00%.
.jpg)